NCT06672952

Dose-Response Impact of Glucosyl-Hesperidin (CitraPeak) on Exercise Performance, Blood Flow, Stress, Cognition, and Other Perceptual Indicators

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Lindenwood University · Academic / Other
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the dose-dependent effects of glucosyl-hesperidin (CITRAPEAK) supplementation on exercise performance, recovery indicators, blood flow, cognitive function, mood, sleep, and fuel utilization in recreationally active adults.

Detailed description

This randomized, double-blind, placebo-controlled study investigates the effects of glucosyl-hesperidin (CITRAPEAK) on exercise performance, recovery, cognitive function, mood, and cardiovascular health in approximately 60 healthy, recreationally active adults aged 18-50. Participants will be assigned to one of three groups (placebo, 200mg CITRAPEAK, or 400mg CITRAPEAK) based on sex and baseline fat-free mass. Each participant will consume their assigned supplement daily for 8 weeks, with adherence tracked via supplementation logs. The study includes multiple visits, where participants will undergo a range of assessments, including exercise performance tests, blood flow analysis, and cognitive evaluations.

Conditions

• Exercise Performance
• Exercise Recovery
• Cognitive Function
• Nitric Oxide
• Blood Flow
• Endurance Exercise

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	400 mg CITRAPEAK® (glucosyl-hesperidin) supplementation	The active intervention consists of 400 mg of glucosyl-hesperidin (CITRAPEAK®) in capsule form.
DIETARY_SUPPLEMENT	Placebo	The placebo intervention consists of 400 mg/day of cellulose in capsule form, matching the appearance and dosage of active interventions.
DIETARY_SUPPLEMENT	200 mg CITRAPEAK® (glucosyl-hesperidin) supplementation	The active intervention includes 200 mg of glucosyl-hesperidin (CITRAPEAK®) and an additional 200 mg of cellulose in capsule form.

Timeline

• Start date: 2025-04-15
• Primary completion: 2026-01-01
• Completion: 2026-01-01
• First posted: 2024-11-04
• Last updated: 2025-12-12

Locations

1 site across 1 country: United States